Neurocrine Biosciences, Inc.
DE ˙ DB ˙ US64125C1099
134,65 € ↑0,30 (0,22%)
2026-06-03
DEL PRIS
SecurityDE:NB3 / Neurocrine Biosciences, Inc.
InstitutionXponance, Inc.
Latest Disclosed Ownership27,679 shares
Latest Disclosed Value $ 3,646,431
Xponance, Inc. reports 10.67% increase in ownership of NB3 / Neurocrine Biosciences, Inc.

On May 13, 2026 - Xponance, Inc. filed a 13F-HR form disclosing ownership of 27,679 shares of Neurocrine Biosciences, Inc. (DE:NB3) valued at $3,093,128 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 25,010 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 10.67% during the quarter. The current value of the position is $3,726,977 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 27,679 2,669 10.67 3,646 2.79 0.0259
2026-02-12 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 25,010 -1,378 -5.22 3,547 -4.24 0.0266
2025-11-12 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 26,388 413 1.59 3,704 13.48 0.0293
2025-08-14 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 25,975 -1,307 -4.79 3,265 8.19 0.0273
2025-05-01 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 27,282 215 0.79 3,017 -18.33 0.0292
2025-02-11 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 27,067 1,941 7.73 3,695 27.60 0.0337
2024-11-12 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 25,126 -102 -0.40 2,895 -16.64 0.0279
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 25,228 -436 -1.70 3,473 -1.86 0.0355
2024-05-13 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 25,664 4,216 19.66 3,540 25.27 0.0371
2024-01-31 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 21,448 -936 -4.18 2,826 12.19 0.0339
2023-10-24 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 22,384 -55 -0.25 2,518 19.05 0.0343
2023-07-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 22,439 -279 -1.23 2,116 -8.00 0.0282
2023-04-18 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 22,718 386 1.73 2,300 -13.80 0.0336
2023-01-24 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 22,332 1,410 6.74 2,667 20.03 0.0432
2022-10-24 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 20,922 57 0.27 2,222 9.24 0.0427
2022-08-02 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 20,865 537 2.64 2,034 6.72 0.0409
2022-04-20 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 20,328 -92 -0.45 1,906 9.60 0.0317
2022-01-31 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 20,420 -36 -0.18 1,739 -11.37 0.0273
2021-11-05 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 20,456 -159 -0.77 1,962 -2.19 0.0373
2021-08-12 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 20,615 1,146 5.89 2,006 5.97 0.0369
2021-05-10 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,469 9,938 104.27 1,893 107.11 0.0401
2021-02-11 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,531 -96 -1.00 914 -1.30 0.0199
2020-10-26 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,627 94 0.99 926 -20.38 0.0228
2020-08-14 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,533 9,533 1,163 0.0300
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.